Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732446 | 0.94 | CYP2D6 (0.65) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL14218795 | 0.91 | CYP2D6 (0.60) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL16349557 | 0.90 | CYP2D6 (0.59) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9688641 | 0.90 | CYP2D6 (0.59) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL24798656 | 0.89 | CYP2D6 (0.68) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL24798927 | 0.89 | CYP2D6 (0.68) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9689675 | 0.88 | CYP2D6 (0.58) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL18389864 | 0.88 | CYP2D6 (0.64) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL18389865 | 0.88 | CYP2D6 (0.60) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL4292159 | 0.88 | CYP2D6 (0.76) | CYP2D6CYP3A4TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11100381-A | — | — | None | — | — | JP | disclosed |
| JP-11060577-A | — | — | None | — | — | JP | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1781670-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | Cumbre Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006012470-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
| JP-H11100381-A | DIAZASPIRONONANIUM SALT | SHOWA DENKO KK | 1999-04-13 | — | — | JP | disclosed |
| JP-H1160577-A | ORGANIC TEMPLATE FOR SYNTHESIZING ZEOLITE | SHOWA DENKO KK | 1999-03-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | CYP2D6 90/4885CYP3A4 353/4885TSHR 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.